Clinical Trials
52 trialsBrodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
IVY
Eli Lilly and Company
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
DUET-4
Xencor, Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
MICROBIOME
Imperial College London
Safety Study of MGA271 in Refractory Cancer
MacroGenics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
PSX-X04
Viralytics
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
BIND Therapeutics
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
ImmunoFrontier, Inc.
MDX1106-01
Bristol-Myers Squibb
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
Lantheus Biosciences Ltd.
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Memorial Sloan Kettering Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)